Eli Lilly

Mounjaro

Tirzepatide

Dual GIP/GLP-1 agonist with the highest weight loss efficacy in trials.

Type 2 Diabetes 22.5% avg weight loss

83 B+

Response Score

ⓘ For informational purposes only — not medical advice.

Score Breakdown

Overview

Mounjaro (tirzepatide) is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist developed by Eli Lilly. Originally approved for type 2 diabetes, its weight loss efficacy in the SURMOUNT trial program has made it one of the most closely watched molecules in metabolic medicine. The dual-agonist mechanism targets two incretin pathways simultaneously, producing weight loss results that surpassed existing GLP-1-only therapies in head-to-head comparisons.

Mechanism of Action

Tirzepatide activates both GIP and GLP-1 receptors, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central nervous system signaling. The dual mechanism is thought to provide additive metabolic benefits beyond what GLP-1 receptor activation alone achieves, including improved insulin sensitivity and potentially more favorable effects on lipid metabolism.

Clinical Evidence

The SURMOUNT-1 trial demonstrated 22.5% mean body weight reduction at the highest dose (15 mg) over 72 weeks in adults with obesity or overweight without diabetes. SURMOUNT-2 showed 15.7% weight loss in participants with type 2 diabetes. The SURPASS trial program confirmed glycemic superiority over semaglutide 1 mg in type 2 diabetes. Cardiovascular outcome trial data (SURPASS-CVOT) is anticipated.

mRNA Monitoring Insight

Tirzepatide's dual-pathway activation creates a complex transcriptomic signature involving both GIP and GLP-1 receptor-mediated gene expression changes. Biomeme's mRNA monitoring platform can track downstream markers of both pathways simultaneously, providing a more complete picture of metabolic response than single-pathway monitoring. Key gene targets include those involved in lipogenesis suppression, inflammatory resolution, and insulin signaling.

Side Effects & Safety

The most common adverse effects are gastrointestinal: nausea (reported in up to 31% of participants at the highest dose), diarrhea, vomiting, and constipation. Dose-escalation protocols help mitigate GI side effects. There are precautionary warnings regarding thyroid C-cell tumors based on animal studies, pancreatitis, and gallbladder-related events.

FAQ

How does Mounjaro compare to Ozempic for weight loss?

In the SURMOUNT and STEP trial programs, tirzepatide (Mounjaro) demonstrated approximately 22.5% weight loss at the highest dose versus semaglutide's ~15% at comparable doses. However, head-to-head trials comparing the two at optimized doses are still ongoing.

Is Mounjaro FDA-approved for weight loss?

Mounjaro is FDA-approved for type 2 diabetes. The same molecule under the brand name Zepbound is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

Quick Facts

Generic: Tirzepatide
Manufacturer: Eli Lilly
Key Trial: SURMOUNT-1
Score: 83/100 (B+)

Sources

Compare Others

Track Your Mounjaro Response.

Biomeme's GLP-1 Response Panel monitors molecular changes so you know your medication is working — weeks before the scale moves.